- Home
- BJDX vs CNSP Comparison
BJDX vs CNSP Comparison
Compare BJDX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJDX | CNSP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BJDX | CNSP |
|---|---|---|
| Price | $2.00 | $2.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 111.9K | 22.6K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.65 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $249,040.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $55.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.73 |
| 52 Week High | $10.20 | $10.59 |
Technical Indicators
Market Signals| Indicator | BJDX | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 31.94 |
| Support Level | $1.43 | $0.86 |
| Resistance Level | $2.47 | $8.89 |
| Average True Range (ATR) | 0.16 | 0.34 |
| MACD | -0.05 | 0.10 |
| Stochastic Oscillator | 48.98 | 8.06 |
Price Performance
Historical ComparisonAbout BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.